BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32320335)

  • 21. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.
    le Maignan C; Desablens B; Delwail V; Dib M; Berthou C; Vigier M; Ghandour C; Atmani S; Casassus P; Maisonneuve H; Le Mevel A; Traulle C; Bernard M; Briere J; Colonna P; Andrieu JM
    Blood; 2004 Jan; 103(1):58-66. PubMed ID: 12907440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N; Jais JP; Tomowiack C; Colombat P; Berthou C; Desablens B; Moles-Moreau MP; Gastinne T; Quittet P; Casassus P; Le Pourhiet-Le Mevel A; Ghandour C; Brière J; Colonna P; Andrieu JM
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma].
    Torrent A; Navarro JT; Andreo FC; Ribera JM
    Med Clin (Barc); 2013 Aug; 141(3):134-5. PubMed ID: 23332624
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma.
    Jóna Á; Miltényi Z; Póliska S; Bálint BL; Illés Á
    PLoS One; 2016; 11(6):e0157651. PubMed ID: 27327270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency distribution of BLMH, XPO5 and HFE gene polymorphisms in the South Indian population and their association with Hodgkin Lymphoma.
    Thakkar DN; Palugulla S; Selvarajan S; Dubashi B
    Int J Biol Markers; 2018 Mar; ():1724600818766502. PubMed ID: 29683071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
    Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.
    Avivi I; Hardak E; Shaham B; Igla M; Rowe JM; Dann EJ
    Ann Hematol; 2012 Feb; 91(2):215-21. PubMed ID: 21603918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary toxicity following bleomycin use: A single-center experience.
    Madabhavi I; Modi G; Patel A; Anand A; Panchal H; Parikh S
    J Cancer Res Ther; 2017; 13(3):466-470. PubMed ID: 28862210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
    Bröckelmann PJ; McMullen S; Wilson JB; Mueller K; Goring S; Stamatoullas A; Zagadailov E; Gautam A; Huebner D; Dalal M; Illidge T
    Br J Haematol; 2019 Jan; 184(2):202-214. PubMed ID: 30239982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
    Abramson JS; Arnason JE; LaCasce AS; Redd R; Barnes JA; Sokol L; Joyce R; Avigan D; Neuberg D; Takvorian RW; Hochberg EP; Bello CM
    Blood; 2019 Aug; 134(7):606-613. PubMed ID: 31186274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radionuclide ventriculography detects early anthracycline cardiotoxicity in children with Hodgkin lymphoma.
    Tantawy AA; Elmasry OA; Shaaban M; Toaima DN; El Shahat AM
    J Pediatr Hematol Oncol; 2011 May; 33(4):e132-7. PubMed ID: 21516011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
    Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
    J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity.
    Jóna Á; Miltényi Z; Ujj Z; Garai I; Szilasi M; Illés Á
    Expert Opin Drug Saf; 2014 Oct; 13(10):1291-7. PubMed ID: 25135756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.